Staying informed and working closely with your healthcare provider will be important
Although both pharmacological approaches target GLP-1, important differences exist concerning the mode of administration (subcutaneous injection versus oral ingestion), the efficacy (better with GLP-1 agonists), the effects on body weight and systolic blood pressure (diminution with agonists versus neutrality with gliptins), the tolerance profile (nausea and possibly vomiting with agonists) and the cost (higher with GLP-1 receptor agonists)
Ensure the compounding pharmacy follows strict quality standards
Eli Lillys explanation about who it will consider for expanded access broadly follows the widely held understanding of the term, including the stipulation that eligible patients must have a serious or life-threatening illness with no comparable or satisfactory alternative therapies. Thats partly why the decision to grant expanded access for a medication primarily known for weight loss raised so many questions
NAION causes sudden, painless vision loss in one eye when blood flow to the optic nerve is reduced
First, confirm the basics
